Stock comparison
Geron
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GERN
Geron
Market cap
$821.15M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GERN | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 79B | HALO |
| Benjamin Graham | 63D | 83A | HALO |
| Philip Fisher | 52C | 65B | HALO |
| Peter Lynch | 20F | 53D | HALO |
| Joel Greenblatt | 2F | 40D | HALO |
| Charlie Munger | 43D | 80C | HALO |
| Terry Smith | 48D | 84A | HALO |
Side-by-side metrics
| Metric | GERN | HALO |
|---|---|---|
| Market cap | $821.15M | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | -7.77% | 23.65% |
| Gross margin | 86.59% | 81.24% |
| Net margin | -35.48% | 23.13% |
| Revenue CAGR 5y | 2.39% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 1.1x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GERN leads on
- EV/EBIT-vs 10.2x+157%
- P/E (TTM)-vs 24.0x+149%
- Revenue CAGR 5y2.39%vs 33.23%+86%
- Gross margin86.59%vs 81.24%+6%
HALO leads on
- Net margin23.13%vs -35.48%+165%
- ROIC (TTM)23.65%vs -7.77%+133%
- Market cap$8.1Bvs $821.15M+90%
- Debt / Equity1.0xvs 1.1x+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.